Axcella Health: Surges on positive results for liver disease drugs

Axcella Health

06/05/2020 15:49

** Shares of biotech company  AXLA.O  surge 37.45% to $6.68 
    ** Company reports positive data from study of AXA1125 and
AXA1957 drugs for treating adults with non-alcoholic fatty liver
disease (NAFLD)  urn:newsml:reuters.com:*:nBw475L3Ma
    ** NAFLD is characterized by accumulation of excessive liver
fat in people who consume little to no alcohol, and is the most
common form of chronic liver disease in the United States 
    ** AXA1125 and AXA1957 were generally well-tolerated and
effectively regulated key biomarkers of metabolism, inflammation
and fibrosis over 16 weeks - AXLA
    ** Company plans to discuss investigational new drug
application for AXA1125 and proposed Phase 2b clinical trial in
adults and a pediatric development program with U.S. FDA - AXLA
President and CEO Bill Hinshaw
    ** AXLA stock up 63.34% so far this year

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))